Table 1—

Subjects characteristics

Subject nSex m/fAge yrsHeight cmWeight kgAllergy#+/−Total IgE IE·mL−1PC20 FEV1 mg·mL−1·Mch−1ΔFEV1 %VC LFEV1 %predFEV1/VC %Treatment
1m3617271+390.10−15.94.9296.175.4β2
2m2918298+1720.09−21.74.8373.968.7β2
3f3216565+7100.06−27.53.3997.890.0-
4m3118569+2870.14−22.15.30100.987.0β2
5m3516868+230.19−24.04.4570.759.1β2 FLU
6f4717061+1050.04−54.44.0880.658.1β2
7f2517060+5220.04−31.04.67105.478.8β2 BUD
8m28190102+4780.12−30.56.15107.084.7β2 FLU
9f4318185+390.04−16.84.2082.468.1β2 FLU
10f2717575+1700.15−46.24.1894.882.5β2 BDP
11m3218177+3440.26−22.85.5391.772.3β2
12m3418580+820.33−27.95.99104.077.8β2
13m3417672+3400.10−24.65.5895.469.9β2 BUD
14m2718787+8430.08−22.76.1185.166.4β2
15m2619398+1650.09−28.07.64113.975.3β2
16m3518676+2840.78−46.65.4790.974.6β2 BDP
17m3619172+720.13−39.86.3182.160.9β2 BDP
18m2517672+7350.12−38.24.3870.369.9β2
19f3016557+19080.12−25.13.4691.884.1β2 BDP
20m3018681+1780.20−21.75.0789.281.7β2
21f4816878+630.26−45.73.8681.059.6β2
22m3218368+1840.29−48.05.75102.079.0β2
23f37176119+4990.07−49.03.7776.769.8β2 BUD
24f3015849300.16−29.23.4294.880.1β2 BUD
25f3616860+770.03−16.33.1379.379.6β2
Mean ±sd33.0±6.1177.5±9.476.0±15.7334±4050.12±2.16+−31.0±11.54.87±1.1290.3±11.874.1±9.0
  • IgE: immunoglobulin-E

  • FEV1: forced expiratory volume in one second

  • PC20: provocative concentration causing a 20% fall in FEV1

  • Mch: metacholine

  • VC: vital cpacity

  • m: male

  • f: female

  • β2: β2-agonists as needed

  • FLU: fluticasone

  • BUD: budesonide

  • BDP: beclomethasone

  • #: skin prick test with a positive response against ≥20 at least one of 20 common allergens

  • : fall in FEV1 after exercise at screening (% of baseline)

  • +: geometric mean (SD expressed as a factor)